# Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Study · id `cardio:ct-nct06297603` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06297603](<https://clinicaltrials.gov/study/NCT06297603>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06297603

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 341 participants.

## Technical summary

Registry record NCT06297603. Randomized; double masking; primary purpose treatment. Start 2024-03-15 (actual); primary completion 2026-10-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 341 participants (enrolled count; ClinicalTrials.gov record NCT06297603, source copy `cardio:ctgov-nct06297603-2026-11-17`, retrieved 2026-11-18)
- Started: 2024-03-15 (actual) (ClinicalTrials.gov record NCT06297603, source copy `cardio:ctgov-nct06297603-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2026-10-26 (actual) (ClinicalTrials.gov record NCT06297603, source copy `cardio:ctgov-nct06297603-2026-11-17`, retrieved 2026-11-18)
- Completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT06297603, source copy `cardio:ctgov-nct06297603-2026-11-17`, retrieved 2026-11-18)
- Countries: United States; Argentina; Brazil; Israel; Mexico; Puerto Rico; United Kingdom (ClinicalTrials.gov record NCT06297603, source copy `cardio:ctgov-nct06297603-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06297603-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
- Condition: Type 2 Diabetes
- Intervention (Drug): Retatrutide
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 171f12618f5d39df9e11346e1aaa00bb5a765df5d64070fa9e5536b4d36fad80
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
